123 related articles for article (PubMed ID: 3534285)
1. Monoclonal antibodies (Mabs) in head and neck cancer.
Poliquin JF; Filion LG
J Otolaryngol; 1986 Oct; 15(5):289-92. PubMed ID: 3534285
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of monoclonal antibodies for detection and treatment of head and neck tumours.
Quak J; Gerretsen M; De Bree R; Brakenhof R; Van Dongen G; Snow G
Anticancer Res; 1993; 13(6B):2533-9. PubMed ID: 8135493
[TBL] [Abstract][Full Text] [Related]
3. Development of monoclonal antibodies with specificity to oral squamous cell carcinoma.
Fantozzi RD
Laryngoscope; 1991 Oct; 101(10):1076-80. PubMed ID: 1921634
[TBL] [Abstract][Full Text] [Related]
4. [Possibilities for using monoclonal antibodies in diagnosis and therapy of head and neck cancers. I. Introduction and current state].
Wustrow TP
HNO; 1991 Mar; 39(3):82-90. PubMed ID: 2050556
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in head and neck cancer: current practice and future possibilities.
Agada FO; Alhamarneh O; Stafford ND; Greenman J
J Laryngol Otol; 2009 Jan; 123(1):19-28. PubMed ID: 18761763
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy: a new alternative treatment for head and neck squamous cell carcinoma].
Bron L; Romero P
Bull Cancer; 2007 Sep; 94(9):793-7. PubMed ID: 17878099
[TBL] [Abstract][Full Text] [Related]
7. MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer.
Andratschke M; Pauli C; Stein M; Chaubal S; Wollenberg B
Anticancer Res; 2003; 23(2B):1467-71. PubMed ID: 12820411
[TBL] [Abstract][Full Text] [Related]
8. [Monoclonal antibody UW 21/123: clinical use and diagnostic specificity in head and neck cancers].
Zenner HP; Herrmann IF; Moser L
Laryngol Rhinol Otol (Stuttg); 1986 May; 65(5):287-91. PubMed ID: 3016433
[TBL] [Abstract][Full Text] [Related]
9. Squamous cell carcinoma-associated antigens used in novel strategies for the detection and treatment of minimal residual head and neck cancer.
van Dongen GA; Brakenhoff RM; ten Brink CT; van Gog FB; de Bree R; Quak JJ; Snow GB
Anticancer Res; 1996; 16(4C):2409-13. PubMed ID: 8816843
[TBL] [Abstract][Full Text] [Related]
10. Head and neck cancer antigens recognized by the humoral immune system.
Monji M; Senju S; Nakatsura T; Yamada K; Sawatsubashi M; Inokuchi A; Nishimura Y
Biochem Biophys Res Commun; 2002 Jun; 294(3):734-41. PubMed ID: 12056832
[TBL] [Abstract][Full Text] [Related]
11. The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas.
Bei R; Masuelli L; Trono P; Orvietani PL; Losito S; Marzocchella L; Vitolo D; Albonici L; Mrozek MA; Di Gennaro E; Lista F; Faggioni G; Ionna F; Binaglia L; Manzari V; Budillon A; Modesti A
Int J Oncol; 2007 Dec; 31(6):1301-8. PubMed ID: 17982655
[TBL] [Abstract][Full Text] [Related]
12. Detection and localization of tumor-associated immune components of head and neck squamous cell carcinomas.
Popović D; Gill L; Sisson G; Applebaum E; Anderson B
Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol; 1976; 82(2):119-30. PubMed ID: 59450
[No Abstract] [Full Text] [Related]
13. [Production and preclinical use of a monoclonal immunotoxin against laryngeal cancer cells].
Zenner HP
Laryngol Rhinol Otol (Stuttg); 1984 Nov; 63(11):566-9. PubMed ID: 6521585
[TBL] [Abstract][Full Text] [Related]
14. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
[TBL] [Abstract][Full Text] [Related]
15. Head and neck tumour immunology: basic concepts and new clinical implications.
Topping KP; Fletcher LM; Agada FO; Alhamarneh O; Stafford ND; Greenman J
J Laryngol Otol; 2009 Jan; 123(1):9-18. PubMed ID: 18761764
[TBL] [Abstract][Full Text] [Related]
16. Expression of cancer testis antigens in head and neck squamous cell carcinomas.
Figueiredo DL; Mamede RC; Proto-Siqueira R; Neder L; Silva WA; Zago MA
Head Neck; 2006 Jul; 28(7):614-9. PubMed ID: 16475205
[TBL] [Abstract][Full Text] [Related]
17. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
18. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM; Shuler C
J Oral Pathol Med; 2006 Oct; 35(9):560-7. PubMed ID: 16968237
[TBL] [Abstract][Full Text] [Related]
19. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy.
Vrouenraets MB; Visser GW; Stigter M; Oppelaar H; Snow GB; van Dongen GA
Cancer Res; 2001 Mar; 61(5):1970-5. PubMed ID: 11280754
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck.
Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M
J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
